Giordani A S, Candelora A, Fiacca M, Cheng C, Barberio B, Baritussio A, Marcolongo R, Iliceto S, Carturan E, De Gaspari M, Rizzo S, Basso C, Tarantini G, Savarino E V, Alp Caforio
Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua and Azienda Ospedale Università di Padova, Padua, Italy.
Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua and Azienda Ospedale Università di Padova, Padua, Italy.
Int J Cardiol. 2023 Apr 1;376:165-171. doi: 10.1016/j.ijcard.2023.01.071. Epub 2023 Feb 3.
Myocarditis and inflammatory bowel diseases (IBD) are rare conditions, but may coexist. Myocarditis in IBD may be infective, immune-mediated, or due to mesalamine toxicity. A gap of knowledge exists on the clinical features of patients that present myocarditis in association with IBD, especially for endomyocardial biopsy-proven cases. Our aims are: 1) to describe the clinical characteristics of patients with an associated diagnosis of myocarditis and IBD in a single-center hospital, 2) to perform a systematic review of the literature of analogous cases.
We retrospectively analyzed data of patients followed up at the outpatient Cardio-immunology and Gastroenterology Clinic of Padua University Hospital, to identify those with an associated diagnosis of myocarditis and IBD. In addition, a systematic review of the literature was conducted. We performed a qualitative analysis of the overall study population.
The study included 104 patients (21 from our single center cohort, 83 from the literature review). Myocarditis in IBD more frequently affects young (median age 31 years) males (72%), predominantly with infarct-like presentation (58%), within an acute phase of the IBD (67%) and with an overall benign clinical course (87%). Nevertheless, a not negligible quote of patients may present giant cell myocarditis, deserve immunosuppression and have a chronic, or even fatal course. Histological evidence of mesalamine hypersensitivity is scarce and its incidence may be overestimated.
Our study shows that myocarditis in association with IBD, if correctly managed, may have a spontaneous benign course, but predictors of worse prognosis must be promptly recognized.
心肌炎和炎症性肠病(IBD)均较为罕见,但可能同时存在。IBD中的心肌炎可能是感染性、免疫介导性的,或由美沙拉嗪毒性所致。对于合并IBD的心肌炎患者的临床特征,尤其是经心内膜心肌活检证实的病例,目前存在知识空白。我们的目的是:1)描述单中心医院中合并心肌炎和IBD诊断的患者的临床特征,2)对类似病例的文献进行系统综述。
我们回顾性分析了帕多瓦大学医院门诊心脏免疫学和胃肠病学诊所随访患者的数据,以确定那些合并心肌炎和IBD诊断的患者。此外,还对文献进行了系统综述。我们对整个研究人群进行了定性分析。
该研究纳入了104例患者(21例来自我们的单中心队列,83例来自文献综述)。IBD中的心肌炎更常累及年轻男性(中位年龄31岁,占72%),主要表现为梗死样(58%),处于IBD的急性期(67%),且总体临床病程良性(87%)。然而,仍有相当一部分患者可能表现为巨细胞心肌炎,需要免疫抑制治疗,且病程呈慢性,甚至可能致命。美沙拉嗪超敏反应的组织学证据较少,其发生率可能被高估。
我们的研究表明,合并IBD的心肌炎若得到正确处理,可能有自发的良性病程,但必须及时识别预后较差的预测因素。